Other

Universitat Leipzig

Phytrix Ag

Rolf Gebhardt

Christoph Gleiter

Michael Manns

Lusine Danielyan

Hildebert Wagner

Gayane Buniatian

Barbara Proksch

Angelika M Vollmar

Matthias Bahr

Gayane Hrachia Buniatian

The present invention relates to the therapeutic use of activators of the zinc finger protein GLI3 in diseases that are associated with reduced Hedgehog signaling in hepatocytes, in particular Polycystic ovary syndrome, Steatosis hepatis, Steatohepatitis and/or Adipositas. The invention further relates to methods of treating an individual with said activator, a pharmaceutical composition comprising said activator and the use of said activator as food supplement.

Therapeutic use of activators of zinc finger protein GL13

The present invention relates to a method for the treatment of organs which are degenerative and/or in the pathological state by means of the use of cells, which are phenotypically stably differentiating or differentiated but not necessarily ultimately predetermined with respect to development, from a donor organ selected according to the principles of the opposite cell differentiation program (OCDP) and also to the use of cells of this type for the treatment or for the production of a drug for treatment of the same. Furthermore, the present invention relates to pharmaceutical agents comprising suitable phenotypically stable cells, cells of a first organ which is different from the second organ with respect to organ type thereby being used, which, in the normal physiological state with respect to a predetermined set of expressed genes and/or phenotypical properties, have opposite properties to the second cells in the normal physiological state.

Use of the opposite cell differentiation program (OCDP) for the treatment of degenerated organs in the pathological state

The present invention relates to the use of Phyllanthus for preventing or treating connective tissue proliferations, for maintaining the level of reduced glutathione, for inhibiting lipopolysaccharide (LPS)-induced nitric oxide synthase (NOS) and for inhibiting expression of the cyclooxygenase (COX-2) protein.

Use of Phyllanthus for treating chronic inflammatory and fibrotic processes

The invention relates to a drug for treating or preventing intrahepatic cholestasis, which is characterized by containing as active agent at least one compound with the general formula I,

Anticholestatic effect of luteolin

In a perifusion apparatus for culturing living cells, the culture medium and the gas in the culture chamber are separated from one another by a gas-permeable wall, the liquid area being entirely filled with the culture medium. Gassing takes place through the gas-permeable wall. Several culture chambers can be interconnected as plug-in modules in such a way that common means can be used for liquid circulation, gassing and optionally thermizing.

Growing community of inventors

Leipzig, Germany

Rolf Gebhardt